脈絡膜新生血管市場：製品タイプ、治療タイプ、疾患タイプ、エンドユーザー別-2025-2030年の世界予測

脈絡膜新生血管市場は、2023年に59億5,000万米ドルと評価され、2024年には63億8,000万米ドルに達すると予測され、CAGR 7.57％で成長し、2030年には99億3,000万米ドルになると予測されています。

脈絡膜新生血管（CNV）は眼球の脈絡膜層に新生血管が形成されるもので、重度の視力障害や加齢黄斑変性（AMD）などの疾患につながることが多いです。CNV治療市場は、世界の高齢化によりAMDの有病率が上昇しているため、革新的な治療アプローチが求められていることが背景にあります。現在の治療には、抗VEGF（血管内皮増殖因子）療法、レーザー治療、光線力学的療法などがあり、エンドユーザーは眼科クリニック、病院、眼科専門医療センターなどに及んでいます。市場成長は、ドラッグデリバリーシステムの進歩、患者の意識の高まり、治療効果の改善に焦点を当てた継続的な研究によって影響を受けています。さらに、特に生物製剤と遺伝子治療における技術革新は、企業にとって製品ポートフォリオを拡大する大きな機会となっています。しかし、治療費の高騰、規制上のハードル、潜在的な副作用といった課題もあり、より効果的で手ごろな価格の解決策を確保するためには、継続的な調査と技術革新が必要です。

主なビジネスチャンスは、徐放性製剤の開発と個別化医療にあり、個別化治療計画のために遺伝子マーカーを活用します。企業は、患者の転帰を改善しうる新規作用機序や併用療法を探求するための共同研究に投資することができます。このような治療機会があるにもかかわらず、市場は治療抵抗性やCNV病態生理の複雑さといった限界に直面しており、これが普遍的な治療法の開発を複雑にしています。さらに、経済的要因やヘルスケアへのアクセスの問題は、特に低所得地域における市場浸透の課題となっています。高い可能性を秘めた技術革新の分野には、治療プロトコルを最適化するためのAI支援診断や、CNV組織を正確にターゲットとし、周囲の眼構造への付随的損傷を軽減するように設計されたナノテクノロジー強化ドラッグデリバリーシステムなどがあります。事業成長のためには、研究機関との提携に注力し、世界規模の臨床試験に積極的に参加することで、新たな動向や技術に関する貴重な考察を得ることができ、ダイナミックに進化する市場競争の中で企業が競争力を維持するのに役立ちます。

市場力学：急速に進化する脈絡膜新生血管市場の主要市場インサイトを公開

脈絡膜新生血管市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 高齢化社会における加齢黄斑変性（AMD）および関連疾患の有病率の増加
  • 早期診断と治療に対する意識の高まり
• 市場抑制要因
  • 治療費の高騰によるアクセシビリティの低下
• 市場機会
  • 網膜画像を用いた早期診断のための人工知能の活用
  • 治療回数を減らすための徐放性インプラントや注射の開発
• 市場の課題
  • 現在の治療に伴う副作用や合併症の可能性

ポーターの5つの力：脈絡膜新生血管市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：脈絡膜新生血管市場における外部からの影響の把握

外部マクロ環境要因は、脈絡膜新生血管市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析脈絡膜新生血管市場における競合情勢の把握

脈絡膜新生血管市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス脈絡膜新生血管市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、脈絡膜新生血管市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨脈絡膜新生血管市場における成功への道筋を描く

脈絡膜新生血管市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 高齢化社会における加齢黄斑変性症（AMD）および関連疾患の罹患率の増加
    • 早期診断と治療に関する意識の向上
  • 抑制要因
    • 治療費が高額でアクセスが制限される
  • 機会
    • 網膜画像を用いた早期診断に人工知能を活用する
    • 治療頻度を減らすための持続放出インプラントと注射剤の開発
  • 課題
    • 現在の治療法に伴う潜在的な副作用と合併症
• 市場セグメンテーション分析
  • 製品タイプ：標的とする作用機序と有効性により、生物学的製剤の好感度が高まっています。
  • エンドユーザー：レーザー療法、抗 VEGF注射、光線力学療法など、幅広い治療オプションが存在するため、病院でのニーズが高まっています。
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 脈絡膜新生血管市場：製品タイプ別

• 生物学的製剤
• デバイス
• 薬物

第7章 脈絡膜新生血管市場治療の種類別

• 抗VEGF薬
• レーザー光凝固術
• 光線力学療法

第8章 脈絡膜新生血管市場：疾患タイプ別

• タイプ1
• タイプ2
• タイプ3

第9章 脈絡膜新生血管市場：エンドユーザー別

• 病院
• 眼科クリニック
• 調査機関

第10章 南北アメリカの脈絡膜新生血管市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の脈絡膜新生血管市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの脈絡膜新生血管市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • バイオコン・バイオロジクスは、アフリベルセプトと互換性のある眼科用バイオシミラーであるイェサフィリのFDA承認を取得し、市場の成長を目指しています。
  • 参天製薬とバイエル薬品は、高濃度処方でnAMDとDMEの治療を改善するアイリーア8mgを日本で発売しました。
  • サンドス、コヒーラス・バイオサイエンスからバイオシミラーラニビズマブCIMERLIを1億7,000万米ドルで買収、眼科市場での存在感とポートフォリオを強化
• 戦略分析と提言

企業一覧

• Adverum Biotechnologies
• Apellis Pharmaceuticals, Inc.
• Astellas Pharma Inc.
• Bausch+Lomb Corporation
• Bausch Health
• Bayer AG
• Biogen, Inc.
• Chugai Pharmaceutical Co., Ltd.
• Clearside Biomedical
• F. Hoffmann-La Roche Ltd.
• Genentech USA, Inc.
• Genentech, Inc.
• Iveric Bio
• Kodiak Sciences
• Kodiax Pharmaceuticals
• Novartis AG
• PulseSight Therapeutics
• Regeneron Pharmaceuticals Inc.
• Samsung Bioepis.
• Sandoz Inc.
• Santen Pharmaceutical Co. Ltd.

LIST OF FIGURES

• FIGURE 1. CHOROIDAL NEOVASCULARIZATION MARKET RESEARCH PROCESS
• FIGURE 2. CHOROIDAL NEOVASCULARIZATION MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. CHOROIDAL NEOVASCULARIZATION MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. CHOROIDAL NEOVASCULARIZATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CHOROIDAL NEOVASCULARIZATION MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CHOROIDAL NEOVASCULARIZATION MARKET DYNAMICS
• TABLE 7. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DEVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LASER PHOTOCOAGULATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TYPE 1, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TYPE 2, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TYPE 3, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. CANADA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 37. CANADA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 38. CANADA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 39. CANADA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. UNITED STATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 52. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 55. AUSTRALIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 56. AUSTRALIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 57. AUSTRALIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 59. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 60. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 61. CHINA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 62. INDIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 63. INDIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 64. INDIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 65. INDIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 67. INDONESIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 68. INDONESIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 69. INDONESIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 71. JAPAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 72. JAPAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 73. JAPAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 75. MALAYSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 76. MALAYSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 77. MALAYSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 79. PHILIPPINES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 80. PHILIPPINES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 81. PHILIPPINES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 83. SINGAPORE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 84. SINGAPORE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 85. SINGAPORE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH KOREA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH KOREA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 89. SOUTH KOREA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 91. TAIWAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 92. TAIWAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 93. TAIWAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 95. THAILAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 96. THAILAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 97. THAILAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 99. VIETNAM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 100. VIETNAM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 101. VIETNAM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 104. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 105. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 106. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 108. DENMARK CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 109. DENMARK CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 110. DENMARK CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 112. EGYPT CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 113. EGYPT CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 114. EGYPT CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 116. FINLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 117. FINLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 118. FINLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 120. FRANCE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 121. FRANCE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 122. FRANCE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 124. GERMANY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 125. GERMANY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 126. GERMANY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 128. ISRAEL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 129. ISRAEL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 130. ISRAEL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 131. ITALY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 132. ITALY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 133. ITALY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 134. ITALY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 136. NETHERLANDS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 137. NETHERLANDS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 138. NETHERLANDS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 140. NIGERIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 141. NIGERIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 142. NIGERIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 144. NORWAY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 145. NORWAY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 146. NORWAY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 147. POLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 148. POLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 149. POLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 150. POLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 151. QATAR CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 152. QATAR CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 153. QATAR CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 154. QATAR CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 156. RUSSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 157. RUSSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 158. RUSSIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 160. SAUDI ARABIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 161. SAUDI ARABIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 162. SAUDI ARABIA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 168. SPAIN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 169. SPAIN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 170. SPAIN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 172. SWEDEN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 173. SWEDEN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 174. SWEDEN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 176. SWITZERLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 177. SWITZERLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 178. SWITZERLAND CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 180. TURKEY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 181. TURKEY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 182. TURKEY CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 184. UNITED ARAB EMIRATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 185. UNITED ARAB EMIRATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 186. UNITED ARAB EMIRATES CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 188. UNITED KINGDOM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
• TABLE 189. UNITED KINGDOM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 190. UNITED KINGDOM CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 191. CHOROIDAL NEOVASCULARIZATION MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 192. CHOROIDAL NEOVASCULARIZATION MARKET, FPNV POSITIONING MATRIX, 2023

The Choroidal Neovascularization Market was valued at USD 5.95 billion in 2023, expected to reach USD 6.38 billion in 2024, and is projected to grow at a CAGR of 7.57%, to USD 9.93 billion by 2030.

Choroidal Neovascularization (CNV) involves the formation of new blood vessels in the choroid layer of the eye, often linked to severe vision impairment and conditions like age-related macular degeneration (AMD). The market for CNV treatment is driven by the necessity for innovative therapeutic approaches due to the rising prevalence of AMD among aging populations globally. Current applications include anti-VEGF (vascular endothelial growth factor) therapies, laser treatment, and photodynamic therapy, with end-users spanning ophthalmology clinics, hospitals, and specialized eye care centers. Market growth is influenced by advancements in drug delivery systems, increasing patient awareness, and ongoing research focused on improving treatment efficacy. Moreover, technological innovations, particularly in biologics and gene therapy, present significant opportunities for companies to expand their product portfolios. However, challenges such as the high cost of treatments, regulatory hurdles, and potential side effects necessitate continuous research and innovation to ensure more effective and affordable solutions.

Key opportunities lie in the development of sustained-release drug formulations and personalized medicine, leveraging genetic markers for individualized treatment plans. Companies could invest in collaborative research efforts to explore novel mechanisms of action and combination therapies that could enhance patient outcomes. Despite these opportunities, the market faces limitations such as treatment resistance and the complexity of CNV pathophysiology, which complicates the development of universal treatments. Additionally, economic factors and healthcare accessibility issues pose challenges to market penetration, particularly in low-income regions. Areas of innovation with high potential include AI-assisted diagnostics to optimize treatment protocols, and nanotechnology-enhanced drug delivery systems designed to target CNV tissues precisely and reduce collateral damage to surrounding eye structures. For business growth, focusing on partnerships with research institutions and actively participating in global clinical trials can provide valuable insights into emerging trends and technologies, helping firms remain competitive in a dynamic and evolving market landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Choroidal Neovascularization Market

The Choroidal Neovascularization Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of age-related macular degeneration (AMD) and related disorders in aging population
  • Enhanced awareness about early diagnosis and treatment
• Market Restraints
  • High cost of treatment limiting the accessibility
• Market Opportunities
  • Leveraging artificial intelligence for early diagnosis using retinal imaging
  • Developing sustained-release implants and injections for reducing the frequency of treatments
• Market Challenges
  • Potential side effects and complications associated with current treatments

Porter's Five Forces: A Strategic Tool for Navigating the Choroidal Neovascularization Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Choroidal Neovascularization Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Choroidal Neovascularization Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Choroidal Neovascularization Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Choroidal Neovascularization Market

A detailed market share analysis in the Choroidal Neovascularization Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Choroidal Neovascularization Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Choroidal Neovascularization Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Choroidal Neovascularization Market

A strategic analysis of the Choroidal Neovascularization Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Choroidal Neovascularization Market, highlighting leading vendors and their innovative profiles. These include Adverum Biotechnologies, Apellis Pharmaceuticals, Inc., Astellas Pharma Inc., Bausch + Lomb Corporation, Bausch Health, Bayer AG, Biogen, Inc., Chugai Pharmaceutical Co., Ltd., Clearside Biomedical, F. Hoffmann-La Roche Ltd., Genentech USA, Inc., Genentech, Inc., Iveric Bio, Kodiak Sciences, Kodiax Pharmaceuticals, Novartis AG, PulseSight Therapeutics, Regeneron Pharmaceuticals Inc., Samsung Bioepis., Sandoz Inc., and Santen Pharmaceutical Co. Ltd..

Market Segmentation & Coverage

This research report categorizes the Choroidal Neovascularization Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product Type, market is studied across Biologics, Devices, and Drugs.
• Based on Treatment Type, market is studied across Anti-VEGF Drugs, Laser Photocoagulation, and Photodynamic Therapy.
• Based on Disease Type, market is studied across Type 1, Type 2, and Type 3.
• Based on End-User, market is studied across Hospitals, Ophthalmology Clinics, and Research Institutes.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of age-related macular degeneration (AMD) and related disorders in aging population
    • 5.1.1.2. Enhanced awareness about early diagnosis and treatment
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of treatment limiting the accessibility
  • 5.1.3. Opportunities
    • 5.1.3.1. Leveraging artificial intelligence for early diagnosis using retinal imaging
    • 5.1.3.2. Developing sustained-release implants and injections for reducing the frequency of treatments
  • 5.1.4. Challenges
    • 5.1.4.1. Potential side effects and complications associated with current treatments
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product type: Increasing preference for biologics due to their targeted mechanism of action and efficacy.
  • 5.2.2. End-user: Increasing need in hospitals due to presence of a wide range of treatment options, including laser therapy, anti-VEGF injections, and photodynamic therapy.
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Choroidal Neovascularization Market, by Product Type

• 6.1. Introduction
• 6.2. Biologics
• 6.3. Devices
• 6.4. Drugs

7. Choroidal Neovascularization Market, by Treatment Type

• 7.1. Introduction
• 7.2. Anti-VEGF Drugs
• 7.3. Laser Photocoagulation
• 7.4. Photodynamic Therapy

8. Choroidal Neovascularization Market, by Disease Type

• 8.1. Introduction
• 8.2. Type 1
• 8.3. Type 2
• 8.4. Type 3

9. Choroidal Neovascularization Market, by End-User

• 9.1. Introduction
• 9.2. Hospitals
• 9.3. Ophthalmology Clinics
• 9.4. Research Institutes

10. Americas Choroidal Neovascularization Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Choroidal Neovascularization Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Choroidal Neovascularization Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Biocon Biologics receives FDA approval for Yesafili, an ophthalmology biosimilar interchangeable with aflibercept, targeting market growth
  • 13.3.2. Santen Pharmaceutical and Bayer Yakuhin launched Eylea 8mg in Japan to improve nAMD and DME treatment with higher concentration formula
  • 13.3.3. Sandoz USD 170 million acquisition of biosimilar ranibizumab CIMERLI from Coherus BioSciences bolsters ophthalmology market presence and portfolio
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Adverum Biotechnologies
• 2. Apellis Pharmaceuticals, Inc.
• 3. Astellas Pharma Inc.
• 4. Bausch + Lomb Corporation
• 5. Bausch Health
• 6. Bayer AG
• 7. Biogen, Inc.
• 8. Chugai Pharmaceutical Co., Ltd.
• 9. Clearside Biomedical
• 10. F. Hoffmann-La Roche Ltd.
• 11. Genentech USA, Inc.
• 12. Genentech, Inc.
• 13. Iveric Bio
• 14. Kodiak Sciences
• 15. Kodiax Pharmaceuticals
• 16. Novartis AG
• 17. PulseSight Therapeutics
• 18. Regeneron Pharmaceuticals Inc.
• 19. Samsung Bioepis.
• 20. Sandoz Inc.
• 21. Santen Pharmaceutical Co. Ltd.